<DOC>
	<DOCNO>NCT01021878</DOCNO>
	<brief_summary>1 . LOCATION OF STUDY : Multicentric study Brazil . 2 . PURPOSE OF THE STUDY : To measure change HOMA index non-diabetic patient APD expose 7,5 % Icodextrin long-dwell ; compare change produce 2,5 % glucose long-dwell . 3 . PRIMARY OUTCOME : The primary efficacy outcome measure HOMA index set difference regard baseline value variable two group well group , show control glucose metabolism . STAGE OF THE STUDY : Phase IV postmarket study DESIGN : Randomized , open-label , multicenter study . Patients randomize receive either Extraneal ( 7,5 % Icodextrin ) 2.5 % Dianeal long-dwell . SAMPLE SIZE : Randomization Upon completion study TOTAL : 120 60 ExtranealTM 60 30 Dianeal® 60 30 Duration : 1 year .</brief_summary>
	<brief_title>Study Evaluate Effects Icodextrin Versus Dianeal Insulin Resistance Nondiabetic Automated Peritoneal Dialysis Patients</brief_title>
	<detailed_description>1 . SUMMARY OF THE STUDY 1.1 PROTOCOLE TITLE : A RANDOMIZED , OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE EFFECTS OF ICODEXTRIN Vs 2,5 % DIANEAL USED FOR THE LONG-DWELL ON HOMA INDEX IN PREVALENT , NON-DIABETIC , PATIENTS IN AUTOMATED PERITONEAL DIALYSIS ( APD ) 1.2 MAIN RESEARCHERS : Roberto Pecoits Filho , Thyago P. Moraes 1.3 LOCATION OF STUDY : Multicentric study Brazil . 1.4 PURPOSE OF THE STUDY : To measure change HOMA index non-diabetic patient APD expose 7,5 % Icodextrin long-dwell ; compare change produce 2,5 % glucose long-dwell . 1.5 PRIMARY OUTCOME : The primary efficacy outcome measure HOMA index set difference regard baseline value variable two group well group , show control glucose metabolism . 1.6 SECONDARY OUTCOMES : 1.6.1 Other efficacy outcome total UF , long-dwell UF , preprandial glycemia ( take first morning breakfast ) , serum insulin level glycated haemoglobin . 1.6.2 The incidence adverse event measure safety outcome . 1.7 STAGE OF THE STUDY : Phase IV postmarket study 1.8 DESIGN : Randomized , open-label , multicenter study . Patients randomize receive either Extraneal ( 7,5 % Icodextrin ) 2.5 % Dianeal long-dwell . 1.9 SAMPLE SIZE : Randomization Upon completion study TOTAL : 100 60 ExtranealTM 50 30 Dianeal® 50 30 1.12 PHARMACEUTICAL FORM , ROUTE OF DE ADMINISTRATION AND DOSAGE ExtranealTM ( 7.5 % Icodextrin ) solution Peritoneal Dialysis : It label `` solution dialysis '' administer within study period one ( 1 ) year . Available 2 liter bag peritoneal dialysis solution ( Twin Bag ) CAPD , product use long-dwell . Dianeal® PD4 ( 2.5 % Dextrose ) solution Peritoneal Dialysis : It label 2.27 % glucose-based `` solution dialysis '' , administer within study period one ( 1 ) year . Available 2 2.5 liter bag peritoneal dialysis solution ( Twin Bag ) CAPD , product use long-dwell . Duration : 1 year .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Icodextrin</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>1.10.1 Older 18 year old . High PET value , averagehigh averagelow . Cause renal chronic disease diabetes mellitus . Patient APD Prevalent patient APD ( define least 90 total day dialysis therapy ) Not willing participate . A Charlson comorbidity index &gt; 7 , life expectancy &lt; 12 month assess treat physician . Positive VIH . Episodes peritonitis month precede randomization . Significant cardiovascular , metabolic infectious complication month precede randomization . Patients active cancer . Patients known allergy corn starch polymer . Patients unable provide inform consent significant psychiatric disorder mental illness Patients meet adequacy goal several month change dosage regime .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>Renal replacement therapy</keyword>
	<keyword>Dialysis solution</keyword>
	<keyword>Icodextrin</keyword>
</DOC>